The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
about
Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatmentA systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Clinicopathological significance of matrix metalloproteinase-7 protein expression in esophageal cancer: a meta-analysisImpact of Neoadjuvant Chemoradiation on Short-Term Outcomes for Esophageal Squamous Cell Carcinoma Patients: A Meta-analysis.Predicting malignant transformation of esophageal squamous cell lesions by combined biomarkers in an endoscopic screening program.The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer.Expression of TP53, BCL-2, and VEGFA Genes in Esophagus Carcinoma and its Biological Significance.HPV infection and p53 and p16 expression in esophageal cancer: are they prognostic factors?Inter- and intra-observer reproducibility of ADC measurements in esophageal carcinoma primary tumors.Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma.
P2860
Q28086781-956E9F9C-24B9-4EFE-98B0-A2DE35262929Q35218636-BC215843-1B9F-43D1-91FE-C80F98D40F73Q35729088-DABCADEA-29ED-4E36-99E4-0445132308C0Q36045600-8323E6DD-D79F-4420-87AB-7786F64F9D61Q37359615-C5037FE0-2E71-4D78-9F50-59F3F061F711Q38687715-728B6CAE-AB2B-4CB7-BCFD-B55571154B4AQ38806371-A620D90B-C70D-4C8A-B8F8-0A9F087503C0Q39453621-965C74DC-DDEC-458F-BB74-BE22A806E512Q41774309-571A56AF-C8EB-42FF-9E57-C03AAF9072C7Q42377376-F9EAB979-D8D3-4CD8-A85F-DA8CD37A5AECQ47114429-D5FE47BC-D435-42E6-9D25-9C66FC1C1A75Q47154860-E7C54582-09B7-419E-BB3A-95FA9D9294D7Q51497796-D34D5B43-F354-473C-BEF8-5DC0A33F124DQ55317227-D635319F-2170-49D3-87BD-06414640B4DAQ55437617-C95E11D3-677F-4F13-B430-44A5D63AB8A7Q55669873-1647D847-974A-4EB7-B8D3-33A75D0F5F17
P2860
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@ast
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@en
type
label
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@ast
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@en
prefLabel
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@ast
The biomarker TP53 divides pat ...... s. A p53 Research Group study.
@en
P2093
P1476
The biomarker TP53 divides pat ...... es. A p53 Research Group study
@en
P2093
Ahmed Ba-Ssalamah
Brigitte Wolf
Daniela Kandioler
Fritz Wrba
Irene Kührer
Johannes Zacherl
Martina Mittlböck
Michael Hejna
Ronald Zwrtek
Sonja Kappel
P304
P356
10.1016/J.JTCVS.2014.06.079
P407
P577
2014-07-22T00:00:00Z